

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY DOCKET NO. 0040964-0002		SERIAL NO. 10/609,233 TBA	
			FILING TBA		GROUP TBA 1616	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	5,376,666	12/27/1994	Duncia	514	303	11/30/1992
	6,559,313	05/06/2003	Myers, et al.	546	279.1	03/22/2002
	6,174,906	01/16/2001	Elliot, et al.	514	365	10/01/1999
	6,197,762	03/06/2001	Garvey, et al.	514	174	09/18/1998
	5,968,911	10/19/1999	Lawson, et al.	514	46	02/18/1997
	5,873,359	02/23/1999	Zapol, et al.	128	203.12	12/09/1994
	20020115655	08/22/2002	Mehanna, Ahmed S.	514	217.03	10/31/2001
	20010031738	10/18/2001	Schwarz, Margaret A.	514	44	12/15/2000
	20030078190	04/24/2003	Weinberg, Marc S.	514	1	05/24/2002
M	20020132787	09/19/2002	Eljamal, Mohammed, et al.	514	44	09/19/2002
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
M		Canadian Journal of Anesthesia, Volume 49, Number 9, November 2002, Excellence in clinically-related research and knowledge, Cardiopulmonary bypass, Kassiani Theodoraki MD DEAA, Panagiota Rellis MD, Apostolos Thanopoulos MD, Loukas Tsourelis MD, Dimitrios Zarkalis MD, Petros Sfyarakis MD, Theophani Antoniou MD				
M		The England Journal of Medicine, Volume 327, July 9, 1992, Number 2, The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, Stuart Rich, MD, Elizabeth Kaufman, RN, and Paul S. Levy, Sc.D				
EXAMINER			DATE CONSIDERED			
			3/15/06			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 0040964-0002		SERIAL NO.			
			FILING		GROUP			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
M			Eporprosteno (Prostacyclin) and Pulmonary Hypertension, 21 March 2000, Annals of Internal Medicine, Volume 132, Number 6					
i.i			Center Watch, Drugs Approved by the FDA, Drug Name: Remodulin (treprostinil) http://www.centerwatch.com/patient/drugs/drug785.html					
			NO date					
EXAMINER			DATE CONSIDERED					
			3/15/06					

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 0040964-0002		SERIAL NO.		
				FILING		GROUP		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
				<p>Medlineplus, Epoprostenol (Systemic) http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203429.html Treprostinel (Systemic) http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500385.html Drugs Approved by the FDA http://www.centerwatch.com/patient/drugs/dru785.html</p> <p style="text-align: center;">No date</p>				
				<p>Enalaprilat Injection, http://www.bedordlabs.com/products/010-10.html</p> <p style="text-align: center;">No date</p>				

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 0040964-0002		SERIAL NO.			
			FILING		GROUP			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
<u>Texas Heart Institute, Calcium-Channel Blockers, http://www.tmc.edu/thi/calemeds.html</u>								
<i>NO date</i>								
<u>HealthAtoZ, http://www.healthatoz.com/healthatoz/AtoZ/ency/angiotensin-converting_enzyme_inhibition...</u>								
<i>NO date</i>								
EXAMINER 			DATE CONSIDERED 3/15/06					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 0040964-0002		SERIAL NO.	
				FILING		GROUP	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Definition for: Eicosanoid, http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_eicosano.html						
	<i>no date</i>						
	Definition for: Prostaglandin, http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_prostagl.html						
	<i>no date</i>						
EXAMINER			DATE CONSIDERED				
			3/15/04				

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 0040964-0002		SERIAL NO.			
			FILING		GROUP			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		<u>Definition for: Prostacyclin, http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_prostacy.html</u>						
		No date						
		<u>Medlineplus, Treprostinil (Systemic), http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500385.html</u>						
		No date						
EXAMINER			DATE CONSIDERED				3/15/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.